Active substance
Tamoxifen
- SFDA 11
- US FDA 14
- Health Canada 4
- US price lines 2
- NHS prices 4
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Farshias | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 22.20 | Generic · Prescription | Eugia Pharma Specialities Limited | Valid |
| NOLVADEX 10 MG TABs | 10 mg | Tablet · Oral use | 30 Blister | SAR 37.80 | NCE · Prescription | AstraZeneca | Valid |
| NOLVADEX-D TAB 20MG | 20 mg | Tablet · Oral use | 30 Blister | SAR 65.80 | Generic · Prescription | AstraZeneca | Valid |
| NOLVADEX 10 MG TABs | 10 mg | Tablet · Oral use | 250 Tablet Container | SAR 242.50 | NCE · Prescription | AstraZeneca | Withdrawn by MAH · Not Marketed |
| TAMOFEN 10MG TAB | 10 mg | Tablet · Oral use | 100 Tablet Container | SAR 117.90 | Generic · Prescription | BAYER OY | Withdrawn by MAH · Not Marketed |
| TAMOFEN 10MG TAB | 10 mg | Tablet · Oral use | 30 Blister | SAR 24.75 | Generic · Prescription | BAYER OY | Withdrawn by MAH · Not Marketed |
| TAMOFEN 20MG TAB | 20 mg | Tablet · Oral use | 100 Tablet Container | SAR 175.05 | Generic · Prescription | BAYER SCHERING PHARMA | Withdrawn by MAH · Not Marketed |
| TAMOFEN 20MG TAB | 20 mg | Tablet · Oral use | 30 Blister | SAR 56.20 | Generic · Prescription | BAYER SCHERING PHARMA | Withdrawn by MAH · Not Marketed |
| TAMOPHAR 10 MG TABLET | 10 mg | Tablet · Oral use | 30 Blister | SAR 24.75 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| TAMOPLEX 10MG-TAB. | 10 mg | Tablet · Oral use | 30 Blister | SAR 28.00 | Generic · Prescription | PHARMACHEMIE | Withdrawn by regulatory authority · Not Marketed |
| TAMOXIFEN 10MG EBEWE | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 24.20 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE MANIA; BREAST CANCER EARLY HORMONAL; BREAST CANCER MET.HORMONAL; ENDOMETRIAL CANCER; OVARIAN CANCER
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | ACTAVIS LABS FL INC | Prescription | 20 Feb 2003 |
| TAMOXIFEN CITRATE | EQ 20MG BASE; EQ 10MG BASE | tablet · oral | MYLAN | Prescription | 20 Feb 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | DR REDDYS LABS SA | Prescription | 20 Feb 2003 |
| SOLTAMOX | EQ 20MG BASE/10ML | solution · oral | MAYNE PHARMA COMMRCL | Prescription | 29 Oct 2005 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | ZYDUS PHARMS | Prescription | 27 Oct 2017 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | EUGIA PHARMA | Prescription | 14 Aug 2020 |
| NOLVADEX | EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 20MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | ASTRAZENECA | Discontinued | 30 Dec 1977 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 20 Feb 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | ROXANE | Discontinued | 20 Feb 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | ACTAVIS LABS FL INC | Discontinued | 20 Feb 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE | tablet · oral | PHARMACHEMIE | Discontinued | 31 Mar 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | AEGIS PHARMS | Discontinued | 31 Mar 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | TEVA | Discontinued | 28 Apr 2003 |
| TAMOXIFEN CITRATE | EQ 10MG BASE; EQ 20MG BASE | tablet · oral | APOTEX | Discontinued | 23 Sep 2011 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-TAMOX TAB 10MG | 00812404 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-TAMOX TAB 20MG | 00812390 | 20 MG | TABLET · ORAL | APOTEX INC |
| TEVA-TAMOXIFEN | 00851965 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-TAMOXIFEN | 00851973 | 20 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TAMOXIFEN 10 MG TABLET | $0.12555 | per EA | 23 Sep 2026 |
| US NADAC | TAMOXIFEN 20 MG TABLET | $0.27682 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Tamoxifen 10mg tablets | £3.82 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Tamoxifen 10mg/5ml oral solution sugar free | £125.56 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Tamoxifen 20mg tablets | £2.59 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Tamoxifen 40mg tablets | £98.93 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.4. Hormones and antihormones · complementary
Malignant neoplasms of breast; Other specified malignant neoplasms of breast
Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
Safety signals and safety-related labeling changes
- US FDA 25 Sep 2018 SOLTAMOX — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.